Drug development is a race to bring the best treatment options to patients. When it comes to cancer, the stakes are too high not to collaborate to ensure innovative medicines reach patients as soon as possible.

Mablink’s goal is ultimately that more patients can be cured from their cancers, regardless of who is commercializing the drug. Mablink strongly believes that ADC are a part of the answer and that is why we are seeking partners that share our ambition and philosophy to license PSARlinkTM, our Hydrophilic ADC technology.

Get in touch with our CBO, Edouard Leroy (e.leroy [at] mablink [dot] com), to discuss your collaboration project or fill-in our contact form.